Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.78 USD
Change Today +0.018 / 2.36%
Volume 16.9K
ACUR On Other Exchanges
As of 11:21 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

acura pharmaceuticals inc (ACUR) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/18/14 - $1.18
52 Week Low
12/2/14 - $0.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acura pharmaceuticals inc (ACUR) Related Businessweek News

No Related Businessweek News Found

acura pharmaceuticals inc (ACUR) Details

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets for the use as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, hydromorphone HCl, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has collaboration and license agreements with Egalet US, Inc.; Egalet Ltd.; and Egalet Corporation to manufacture and commercialize Oxaydo products worldwide. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.

15 Employees
Last Reported Date: 03/2/15
Founded in 1935

acura pharmaceuticals inc (ACUR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $387.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $280.0K
Vice President of Technical Affairs
Total Annual Compensation: $285.0K
Vice President, Treasurer and Corporate Contr...
Total Annual Compensation: $172.0K
Vice President of Corporate Development
Total Annual Compensation: $172.0K
Compensation as of Fiscal Year 2014.

acura pharmaceuticals inc (ACUR) Key Developments

Acura Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Acura Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $5,357,000 against $42,000 a year ago. Operating income was $1,512,000 against operating loss of $3,826,000 a year ago. Income before income taxes was $1,239,000 against loss before income taxes of $4,088,000 a year ago. Net income was $1,239,000 against net loss of $4,088,000 a year ago. Diluted income per share was $0.03 against LPS of 0.08 a year ago.

Acura Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 04, 2015

Acura Pharmaceuticals, Inc. announced that they will report Q1, 2015 results After-Market on May 04, 2015

Acura Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 05, 2015

Acura Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACUR:US $0.78 USD +0.018

ACUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $2.69 USD +0.09
Johnson & Johnson $99.74 USD -0.30
Perrigo Co PLC $195.55 USD +2.56
View Industry Companies

Industry Analysis


Industry Average

Valuation ACUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.1x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACURA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at